Medical articles today

/* 728x15, */

Prevention Is The Highlight Theme Of This Year's ESC Congress

As the ESC Congress 2009 draws ever closer, the evidence in favour of a healthy lifestyle for the prevention of cardiovascular disease grows ever stronger. Prevention is the highlight theme of this year's event, which will take place in Barcelona from 29 August to 2 September. Lifestyle factors are heavily on the agenda. There is now a substantial body of evidence showing that the adoption of a healthy lifestyle pays huge rewards in the prevention of cardiovascular disease. Indeed, a report in JAMA this week suggests that men who exercised regularly, drank moderately, did not smoke, were not overweight and had a diet that included cereal, fruits and vegetables had a lower lifetime risk of heart failure.

News From Annals Of Internal Medicine, July 21, 2009

HIV Susceptibility Testing Increases Patient Survival The use of HIV susceptibility testing (GPT) can help guide the selection of antiretroviral therapy for HIV-positive patients. Susceptibility testing looks for the presence of HIV mutations that are associated with how well the virus responds to various drugs. Researchers observed 2, 699 HIV-positive patients eligible for susceptibility testing to evaluate the relationship between testing and survival. They found that patients who underwent suseceptibility testing were less likely to die than those who did not have testing. The study authors concluded that more research is needed to determine whether increased survival is due to better treatment selection or because patients who had susceptibility testing also had other types of care that improve survival.

/* 468x60, */

Study Looks At Efficacy, Cardiovascular Risks Of Two HIV Treatments

Patients taking Boehringer Ingelheim's HIV drug Viramune have a lower risk of developing cardiovascular disease than those taking Bristol-Myers Squibb's treatment, Reyataz, according to a study released on Monday at the 5th International AIDS Society conference in Cape Town, South Africa, Reuters reports. "The drug trial, involving 569 participants, yielded that Viramune, while being as effective at suppressing HIV as Bristol Myers' blockbuster Reyataz, had a more favourable effect on patients' cardiovascular risks, as measured by certain blood lipids, " the article states. The study found that "Viramune-treated patients had more than twice the level of HDL cholesterol, known as 'good cholesterol' for its benefitial effect on blood vessels, than those on Reyataz, Boehringer said in a statement, " Reuters reports.

Grant From American Heart Association For Cardiac Myogenesis Research Center At UT Southwestern

UT Southwestern Medical Center researchers Drs. Jay Schneider, Joseph Hill and Eric Olson have been awarded a $2 million grant from the American Heart Association to study the development and mechanisms of generating new cardiac muscle cells. UT Southwestern was one of only three institutions in the country to receive the highly competitive award, which will establish an American Heart Association-Jon Holden DeHaan Foundation Cardiac Myogenesis Research Center. Each center will conduct a number of basic science research projects to learn more about how cardiac muscle cells develop and work together. The AHA grant provides funding through 2012.

Pharmalucence, Inc. Announces FDA Approval For Its Generic Sestamibi Kit

Pharmalucence, Inc., a leading supplier of radiopharmaceutical products, announced that it received approval from the U. S. Food and Drug Administration (FDA) Office of Generic Drugs for its Abbreviated New Drug Application (ANDA) to manufacture and market its Kit for the Preparation of Technetium Tc-99m Sestamibi Injection. The FDA has determined that Pharmalucence's Sestamibi Kit is therapeutically equivalent to Cardiolite® 1, an imaging agent used in evaluating myocardial function and to detect coronary artery disease by localizing myocardial ischemia and infarction. The agent is also for use in breast imaging as a second line diagnostic after mammography to assist in the evaluation of breast lesions.

/* 468x60, */

Local Heart Doctors First In Nation To Announce Active Investigation Of Red Wine Resveratrol Pills, Issue Consumer Precautions

Red wine (resveratrol) pills appear to be the rage these days and a local group of cardiologists wants to lead the way for patients and consumers to learn more about them. They may be among the first U.S. cardiologists to do so. In response to growing inquiries about the heart-healthy properties of red wine pills, a local cardiology group says it will soon begin to study the effects of these pills among their patients with heart problems and suggests consumers consult with knowledgeable doctors before launching into unguided self use. Jacqueline Hollywood M.D., cardiologist with the Advanced Cardiology Institute in Ft. Lee, New Jersey, says so many patients are hearing about the promises of red wine pills that their group decided to learn with their patients rather than leave them to pursue unguided use.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy